Loading...
•
Dec 31, 2022
Teva Q4 2022 Earnings Report
Teva's Q4 2022 earnings were reported, showing a revenue of $3.9 billion and a GAAP diluted loss per share of $(1.10).
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported Q4 2022 revenues of $3.9 billion, a decrease of 5% in U.S. dollars or an increase of 1% in local currency terms compared to Q4 2021. GAAP diluted loss per share was $(1.10), while non-GAAP diluted EPS was $0.71. Cash flow generated from operating activities was $973 million, and free cash flow was $1,140 million.
Revenues in the fourth quarter of 2022 were $3,884 million, a decrease of 5% in U.S. dollars or an increase of 1% in local currency terms, compared to the fourth quarter of 2021.
GAAP diluted loss per share in the fourth quarter of 2022 was $(1.10), compared to $(0.14) in the fourth quarter of 2021.
Non-GAAP diluted EPS in the fourth quarter of 2022 was $0.71, compared to $0.77 in the fourth quarter of 2021.
Cash flow generated from operating activities during the fourth quarter of 2022 was $973 million, compared to $456 million in the fourth quarter of 2021.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Teva provided its 2023 business outlook, with revenues expected to be $14.8 - $15.4 billion, adjusted EBITDA of $4.5 - $4.9 billion, non-GAAP diluted EPS expected to be $2.25 - $2.55, and free cash flow expected to be $1.7 - $2.1 billion.
Challenges Ahead
- Volatile swings in FX can negatively impact revenue and income
Revenue & Expenses
Visualization of income flow from segment revenue to net income